[Drug therapy profile of viloxazine. Open clinical trial with 34 patients].
In an open study with viloxazine in 34 patients we obtained nine excellent results, twelve improvements, eight patients worsened, and five maintained a status quo. The most frequent side effects were gastrointestinal, in particular nausea and vomiting. There was no drug interference with neuroleptics and anxiolitics used simultaneously in the treatment of the patients studied. From this study we can ascertain the existence of three therapeutic dimensions of viloxazine: anxiolytic, energizing, and antidepressive. Doses of 50 to 150 mg., of 150 to 250 or 300 mg., and up to dosages of 400 mg. per diem respectively produce and in that order, the above-mentioned effects.
D001007:Anxiety / Q000188:drug therapy*; D002648:Child; D003863:Depression / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D014745:Viloxazine / Q000009:adverse effects / Q000627:therapeutic use*
D009025:Morpholines; D014745:Viloxazine
Perfil farmacoterapéutico de la viloxacina. Ensayo clínico abierto en 34 pacientes.